GoAI
Get started
PRISM BioLab Co.,LTD logo

PRISM BioLab Co.,LTD

206A.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥170

¥0.00 · 0.00%

Aug 24, 3:30 PM JST

206A.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

PRISM Pharma Co., Ltd. is a pharmaceutical enterprise dedicated to identifying and advancing small molecule compounds. Its core mission involves modulating protein-protein interactions. The company leverages a proprietary protein secondary structure mimetic library to regulate interactions between proteins within cells. A key product in its development pipeline is PRI-724, an anti-cancer CP/Catenin inhibitor. This drug targets both mature cancer cells and cancer stem cells, inducing them to transition from uncontrolled proliferation to differentiation. Hiroyuki Kouji founded the organization on November 2, 2006, and it is headquartered in Fujisawa, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Dai Takehara
Listed since
Jul 2, 2024
Employees
35

Market position

Day range

Current ¥170

52-week range

Current ¥170

Open
¥170
Previous close
¥170
Volume
31.8K
0.2× average
Average volume
159.39K
Average daily volume
Market cap
6.28B JPY
Beta
1.43
Market reference 1
50-day average
¥149.56
+13.67% above average
200-day average
¥170.06
-0.03% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.22B JPY
EV / EBITDA
-3.88×
Earnings yield
-13.58%
Free cash flow yield
-24.98%

Profitability & efficiency

Return on equity
-30.78%
Return on assets
-27.02%
Return on invested capital
-28.52%

Financial health

Current ratio
8.21×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends153%-72%-298%-523%Gross margin, FY2022: 96.53%Gross margin, FY2023: 71.11%Gross margin, FY2024: 52.53%Gross margin, FY2025: 39.83%Operating margin, FY2022: 12.03%Operating margin, FY2023: -439.99%Operating margin, FY2024: -256.00%Operating margin, FY2025: -114.34%Net margin, FY2022: 13.16%Net margin, FY2023: -466.60%Net margin, FY2024: -343.40%Net margin, FY2025: -123.09%FY2022FY2023FY2024FY2025
Gross margin FY2022 96.53%. Gross margin FY2023 71.11%. Gross margin FY2024 52.53%. Gross margin FY2025 39.83%. Operating margin FY2022 12.03%. Operating margin FY2023 -439.99%. Operating margin FY2024 -256.00%. Operating margin FY2025 -114.34%. Net margin FY2022 13.16%. Net margin FY2023 -466.60%. Net margin FY2024 -343.40%. Net margin FY2025 -123.09%.

Income trends

Revenue

677.33M JPY+121.62%

Operating income

−774.45M JPY+1.01%

Net income

−833.7M JPY+20.56%
Income trends across reported periods850.01M JPY159.28M JPY−531.46M JPY−1.22B JPYRevenue, FY2022: 554.4M JPYRevenue, FY2023: 112.93M JPYRevenue, FY2024: 305.62M JPYRevenue, FY2025: 677.33M JPYOperating income, FY2022: 66.68M JPYOperating income, FY2023: −496.87M JPYOperating income, FY2024: −782.39M JPYOperating income, FY2025: −774.45M JPYNet income, FY2022: 72.96M JPYNet income, FY2023: −526.91M JPYNet income, FY2024: −1.05B JPYNet income, FY2025: −833.7M JPYFY2022FY2023FY2024FY2025
Revenue FY2022 554.4M JPY. Revenue FY2023 112.93M JPY. Revenue FY2024 305.62M JPY. Revenue FY2025 677.33M JPY. Operating income FY2022 66.68M JPY. Operating income FY2023 −496.87M JPY. Operating income FY2024 −782.39M JPY. Operating income FY2025 −774.45M JPY. Net income FY2022 72.96M JPY. Net income FY2023 −526.91M JPY. Net income FY2024 −1.05B JPY. Net income FY2025 −833.7M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022
Revenue677.33M JPY305.62M JPY112.93M JPY554.4M JPY
Cost of goods sold407.57M JPY145.08M JPY32.62M JPY19.26M JPY
Gross profit269.76M JPY160.54M JPY80.31M JPY535.14M JPY
Research and development—571.63M JPY338.73M JPY265.88M JPY
Selling, general, and administrative1.04B JPY942.93M JPY238.08M JPY202.1M JPY
Operating expenses1.04B JPY942.93M JPY577.17M JPY468.45M JPY
Interest income5.3M JPY356K JPY19K JPY21K JPY
Interest expense—13.5M JPY——
Depreciation and amortization——8.74M JPY1.21M JPY
Operating income−774.45M JPY−782.39M JPY−496.87M JPY66.68M JPY
Net income−833.7M JPY−1.05B JPY−526.91M JPY72.96M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-6.56

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.69-5.27-9.85-14.43Q4 '24Q1 '25Q2 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 15, 2024: actual -13.42, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual -5.3, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -7.75, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 30, 2025: actual -8.99, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual -0.813, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -7.74, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual -8.6, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -6.56, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates389.77M285.48M181.18M76.89MQ4 '24Q1 '25Q2 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 15, 2024: actual 90.46M JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual 125.65M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 93.03M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Jun 30, 2025: actual 91.06M JPY, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual 367.6M JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual 132M JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual 121M JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 116M JPY, estimate —, surprise —, Comparison unavailable.

206A.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 206A.T

research.disclaimer